SCHEMBL5523592

SCHEMBL5523592

[CH2]NC(=O)Oc1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.52
MAPT P10636 3/20 0.52
RAB9A P51151 1/20 0.50
RAD51 Q06609 1/20 0.50
NFKB1 P19838 1/20 0.49
NFKB2 Q00653 1/20 0.49
RELA Q04206 1/20 0.49
SLC1A3 P43003 1/20 0.49
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
KDM4E B2RXH2 2/20 0.47
THRB P10828 1/20 0.47
GFER P55789 1/20 0.47
GAA P10253 2/20 0.47
HTT P42858 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HSD17B10 Q99714 2/20 0.46
CYP1A2 P05177 2/20 0.46
LMNA P02545 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2551644 0.81 ALDH1A1 (0.55) ALDH1A1MAPTRAB9ARAD51NFKB1
SCHEMBL1444893 0.79 RAD51 (0.56) ALDH1A1MAPTRAB9ARAD51NFKB1
Phenyl Methylcarbamate SCHEMBL27710190 0.78 CYP1A2 (0.54) ALDH1A1MAPTRAB9ARAD51SLC1A3
SCHEMBL9267073 0.77 ALDH1A1 (0.52) ALDH1A1MAPTRAB9ARAD51NFKB1
SCHEMBL13303658 0.77 ALDH1A1 (0.52) ALDH1A1MAPTRAB9ARAD51NFKB1
SCHEMBL5279705 0.77 ALDH1A1 (0.52) ALDH1A1MAPTRAB9ARAD51NFKB1
Phenyl Methylcarbamate SCHEMBL78497 0.77 CYP1A2 (0.57) ALDH1A1MAPTRAB9ARAD51SLC1A3
SCHEMBL21892986 0.77 ALDH1A1 (0.52) ALDH1A1MAPTRAB9ARAD51NFKB1
SCHEMBL21315898 0.77 ALDH1A1 (0.52) ALDH1A1MAPTRAB9ARAD51NFKB1
SCHEMBL14336248 0.77 ALDH1A1 (0.52) ALDH1A1MAPTRAB9ARAD51NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1301527-A2 PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS CORVAS INTERNATIONAL, INC. (US) 2003-04-16 EP claimed
US-20020068702-A1 Novel peptides as NS3-serine protease inhibitors of hepatitis C virus DENDREON PHARMACEUTICALS, INC. 2002-06-06 US claimed
WO-2002008251-A2 PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS CORVAS INTERNATIONAL, INC. (US) 2002-01-31 WO claimed
US-20070219210-A1 Amidopyrazole Derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-09-20 US disclosed
EP-1698626-A1 AMIDOPYRAZOLE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed
US-6737429-B2 TREATMENT OF HIV MEDIATED DISEASES. HOFFMANN-LA ROCHE INC. 2004-05-18 US disclosed
US-20030176465-A1 Cyclic amino acid derivatives MERCK PATENT GMBH (DE) 2003-09-18 US disclosed
US-20030162814-A1 N-substituted 1-amino-1,1-dialkylcarboxylic acid derivatives MERCK PATENT GMBH (DE) 2003-08-28 US disclosed
EP-1329160-A2 4-ACYLAMINOPYRAZOLE DERIVATIVES Sankyo Company, Limited (JP) 2003-07-23 EP disclosed
EP-1303482-A2 N-SUBSTITUTED-1-AMINO-1,1-DIALKYLCARBOXYLIC ACID DERIVATIVES MERCK PATENT GmbH (DE) 2003-04-23 EP disclosed
EP-1301506-A1 CYCLIC AMINO ACID DERIVATIVES MERCK PATENT GmbH (DE) 2003-04-16 EP disclosed
EP-1301527-A2 PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS CORVAS INTERNATIONAL, INC. (US) 2003-04-16 EP disclosed
US-20020068702-A1 Novel peptides as NS3-serine protease inhibitors of hepatitis C virus DENDREON PHARMACEUTICALS, INC. 2002-06-06 US disclosed
US-20020032221-A1 Pyrrole derivatives ROCHE PRODUCTS LIMITED (GB) 2002-03-14 US disclosed
WO-2002008177-A2 N-SUBSTITUTED-1-AMINO-1,1-DIALKYLCARBOXYLIC ACID DERIVATIVES MERCK PATENT GMBH (DE) 2002-01-31 WO disclosed
WO-2002008251-A2 PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS CORVAS INTERNATIONAL, INC. (US) 2002-01-31 WO disclosed
WO-2002006269-A1 CYCLIC AMINO ACID DERIVATIVES MERCK PATENT GMBH (DE) 2002-01-24 WO disclosed
WO-2002002524-A1 PYRROLE DERIVATIVES FOR TREATING AIDS F. HOFFMANN-LA ROCHE AG (CH) 2002-01-10 WO disclosed
US-4353911-A BLOOD CIRCULATION IN BRAIN BUZAS ANDRE 1982-10-12 US disclosed
WO-1979000319-A1 NEW INDOLO(2,3-A)QUINOLIZIDINES,PREPARATION AND THERAPEUTIC USE THEREOF BUZAS ANDRE (FR) 1979-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176465-A1 Cyclic amino acid derivatives F5, F11, F2 ALDH1A1 4386/4885MAPT 4643/4885RAB9A 2355/4885
US-20020068702-A1 Novel peptides as NS3-serine protease inhibitors of hepatitis C virus VIP, TMPRSS15, TMPRSS11D ALDH1A1 2589/4885MAPT 4375/4885RAB9A 1892/4885
US-20030162814-A1 N-substituted 1-amino-1,1-dialkylcarboxylic acid derivatives F5, CCNY, F2 ALDH1A1 1315/4885MAPT 4873/4885RAB9A 2136/4885
US-20070219210-A1 Amidopyrazole Derivative PTGER1, PTGS1, PTGER2 ALDH1A1 171/4885MAPT 4851/4885RAB9A 4058/4885
US-20020032221-A1 Pyrrole derivatives PYCR1, SARS1, MAVS ALDH1A1 2902/4885MAPT 913/4885RAB9A 1540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.